BiotechTube
PDC Biotech

PDC Biotech

Basel, Switzerland· Est.
pdcbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

PDC Therapeutics is a private, pre-revenue biotech leveraging its proprietary Sagitta® biodegradable polymer-drug conjugation platform to develop targeted nanomedicines. The company is at a clinical-stage, with an abstract accepted for the ASCO 2025 meeting, indicating progress in oncology. Led by co-founder and award-winning scientist Prof. Rana Sanyal, the company operates from Basel, Switzerland, and engages in co-development programs with multinational pharmaceutical partners.

Oncology

Technology Platform

Sagitta® biodegradable polymer-drug conjugate (PDC) platform designed to improve therapeutic index, pharmacokinetics, and manufacturability of targeted nanomedicines.

Opportunities

The large and growing oncology market has a high demand for technologies that improve the safety and efficacy of existing chemotherapies.
The flexible Sagitta® platform allows for multiple drug conjugates and partnerships, creating a pipeline-in-a-product opportunity.
Strategic location in Basel facilitates collaboration with major pharmaceutical companies for co-development deals.

Risk Factors

High risk of clinical failure common to all novel drug delivery platforms, including failure to demonstrate superior efficacy over standard therapies.
As a small, pre-revenue start-up, the company faces significant funding and execution risks in advancing costly clinical trials and GMP manufacturing.
Intense competition from other targeted delivery technologies (ADCs, nanoparticles) requires clear differentiation.

Competitive Landscape

PDC Therapeutics competes in the targeted drug delivery space against developers of Antibody-Drug Conjugates (ADCs), lipid nanoparticles, and other polymer-drug conjugate platforms. Its key differentiator is the claimed biodegradability and optimized design of its Sagitta® polymers for an improved therapeutic index. It faces competition from both large pharma and numerous biotech startups.

More companies in Drug Delivery & Formulation →More companies in Switzerland →